NGM Biopharmaceuticals Inc (OQ:NGM)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 333 Oyster Point Blvd
Tel: N/A
IR: See website
Key People
David V. Goeddel
Chairman of the Board
Marc Learned
Executive Director, Research Operations
Jeffrey D. Jonker
William J. Rieflin
Chief Executive Officer, Director
Jin-Long Chen
Founder, Chief Scientific Officer, Director
David J. Woodhouse
Chief Financial Officer
Alex M. DePaoli
Vice President - Clinical Research
Wenyan Shen
Vice President - Biologics
Hui Tian
Vice President - Research
Trombley Wun
Vice President - Business Development
Business Overview
NGM Biopharmaceuticals Inc is a United States-based clinical-stage biopharmaceutical. The Company develops bio therapeutics pipeline that addresses cardiometabolic and liver diseases. It identifies and develops transformational biologics for diabetes, obesity, cardiometabolic diseases, liver disease and immune-oncology. It focuses on discovering the next generation of therapeutics that changes the treatment paradigm for the growing population of diabetes and obesity patients worldwide. Its discovery platform integrates bioinformatics capabilities, relevant animal disease models and a rapid system to assess the physiological activity of prospective targets in the animal models. The Company's developed drug candidates include NGM282, NGN313, NGM386, NGM395, NGM120, NGM217 and NGM621.
Financial Overview
For the fiscal year ended 31 December 2018, NGM Biopharmaceuticals Inc revenues increased 41% to $108.7M. Net loss decreased 97% to $493K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income increase of 54% to $3.6M (income), Other income (expense), net increase from $152K (expense) to $199K (income).
Employees: 164 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $1,128M as of Dec 31, 2018
Annual revenue (TTM): $108.67M as of Dec 31, 2018
EBITDA (TTM): $2.91M as of Dec 31, 2018
Net annual income (TTM): -$0.49M as of Dec 31, 2018
Free cash flow (TTM): -$13.44M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 64,993,706 as of Apr 4, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization